Building the future of targeted immune therapeutics
Currently, Q32 Bio has two programs being evaluated in clinical trials:
Bempikibart (ADX-914)
Adaptive System Modulator
Bempikibart, Q32 Bio’s most advanced product candidate, is a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody (mAb) that is designed to re-regulate adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling. Bempikibart is currently being evaluated in a double-blind, placebo-controlled Phase 2 study in patients with atopic dermatitis (AD) and an additional double-blind, placebo-controlled Phase 2 study in patients with alopecia areata (AA).
ADX-097
Innate System Modulator
ADX-097, the lead product candidate from Q32 Bio’s tissue-targeted complement inhibitor platform, is a humanized anti-C3d mAb fusion protein. ADX-097 is designed to restore complement regulation—an integral part of the innate immune system—through a novel, tissue-targeted mechanism. Q32 Bio is currently evaluating ADX-097 in an open-label Phase 2 renal basket clinical trial and is planning to evaluate ADX-097 in a Phase 2 clinical trial in ANCA-Associated Vasculitis (AAV).